License agreement with Boehringer Ingelheim

12th July 2017 - Munich Systasy Bioscience GmbH and Boehringer Ingelheim International GmbH(BI) entered a non-exclusive license agreement for cell-based splitSENSOR assays providing BI with the options to screen for selected target activities…

Patent transfer of Double Switch Technology from Sygnis AG

May 12, 2014 - Munich Germany Systasy Bioscience GmbH and Sygnis AG closed a patent transfer deal today. A patent transfer agreement for Double Switch technology was signed. Systasy intends to integrate this technology within their EXTassay platformand…